A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861
IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS
- Registry ID
- TAK-861-2003
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- TAKEDA DEVELOPMENT CENTER AMERICAS INC
- Start date
- 2024-11-15
- Last update
- 2024-08-14
Conditions
Related clinical trials
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALKS 2680 IN ADULTS WITH NARCOLEPSY TYPE 1
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF E2086 IN ADULTS WITH NARCOLEPSY
- A LONG-TERM EXTENSION STUDY OF THE SAFETY AND EFFICACY OF CLEMINOREXTON IN PARTICIPANTS WITH NARCOLEPSY AND IDIOPATHIC HYPERSOMNIA WHO COMPLETED A SPONSORED CLEMINOREXTON CLINICAL TRIAL
- A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ORX750 IN SUBJECTS WITH NARCOLEPSY AND IDIOPATHIC HYPERSOMNIA ¿ (CRYSTAL-1)
- A STUDY TO ASSESS THE LONG-TERM EFFICACY AND SAFETY OF AXS-12 IN THE TREATMENT OF CATAPLEXY AND EXCESSIVE DAYTIME SLEEPINESS IN SUBJECTS WITH NARCOLEPSY
- RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF AXS-12 IN THE TREATMENT OF CATAPLEXY AND EXCESSIVE DAYTIME SLEEPINESS IN SUBJECTS WITH NARCOLEPSY
View on source registry